Department of Genomic Sequencing Center, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA, USA.
Department of Translational Molecular Medicine, JWCI at Providence Saint John's Health Center, Santa Monica, CA, USA.
Methods Mol Biol. 2021;2265:475-486. doi: 10.1007/978-1-0716-1205-7_34.
MicroRNAs (miRs) are small RNA molecules (18-22 nucleotides) that regulate the transcriptome at a post-transcriptional level by affecting the expression of specific genes. This regulatory mechanism is critical to maintain cell homeostasis and specific functions. Aberrant expression of miRs have been associated with pathobiological processes including cancer. There are few technologies available that are able to profile whole-genome miR expression using minimal amounts of blood samples and without the need for time-consuming extraction steps. Here, we describe the HTG EdgeSeq miR Whole-Transcriptome Assay (WTA) in serum and plasma samples. To identify specific cell-free miR (cfmiR) patterns we have first focused on the analysis of normal donor samples and have then compared these to patients with cutaneous melanoma. The identification of specific cfmiR for melanoma patients will allow for better patient surveillance during targeted and/or checkpoint inhibitor immunotherapy (CII) treatment.
MicroRNAs (miRs) 是小 RNA 分子(18-22 个核苷酸),通过影响特定基因的表达来在转录后水平调节转录组。这种调节机制对于维持细胞内稳态和特定功能至关重要。miR 的异常表达与包括癌症在内的病理生物学过程有关。目前可用的技术很少能够使用少量的血液样本并避免耗时的提取步骤来分析整个基因组 miR 的表达。在这里,我们描述了 HTG EdgeSeq miR 全转录组分析 (WTA) 在血清和血浆样本中的应用。为了鉴定特定的无细胞 miR (cfmiR) 模式,我们首先专注于正常供体样本的分析,然后将这些与皮肤黑素瘤患者进行比较。鉴定出黑素瘤患者的特异性 cfmiR 将有助于在靶向和/或检查点抑制剂免疫治疗 (CII) 治疗期间更好地监测患者。